Pre-treatment Elevated Platelet Count Associates with HER2 Overexpression and Prognosis in Patients with Breast Cancer

Gu, Mei-Ling; Yuan, Cai-Jun; Liu, Xiao-Mei; Zhou, Yi-Chao; Di, Shu-Huan; Sun, Fei-Fei; Qu, Quan-Ying

추천

검색

자료유형: 학술저널

저자정보: Gu, Mei-Ling (Department of Oncology, The First Affiliated Hospital of Liaoning Medical University) Yuan, Cai-Jun (Department of Oncology, The First Affiliated Hospital of Liaoning Medical University) Liu, Xiao-Mei (Department of Oncology, The First Affiliated Hospital of Liaoning Medical University) Zhou, Yi-Chao (Department of Breast Surgery, The First Affiliated Hospital of Liaoning Medical University) Di, Shu-Huan (Department of Laboratory, The First Affiliated Hospital of Liaoning Medical University) Sun, Fei-Fei (Department of Pathology, The First Affiliated Hospital of Liaoning Medical University) Qu, Quan-Ying (Department of Epidemiology, Liaoning Medical University)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제16권 제13호

발행연도: 2015.1

수록면: 5,537 - 5,540 (4page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Purpose: To research the association between pre-treatment elevated platelet count and clinicopathologic characteristics in breast cancer (BC), as well as explore the relationship between pre-treatment elevated platelet count and HER2 status and prognosis of BC patients. Materials and Methods: A retrospective cohort of BC patients who were newly diagnosed or treated by surgery only and had pathological detection results and platelet values in the Department of Oncology, the First Affiliated Hospital of Liaoning Medical College were enrolled from 1/1/2008 until 31/12/2009, and followed up until 31/12/2014. Age, thrombocyte parameters before chemotherapy and/or radiotherapy, immunohistochemical (IHM) indexes, and regional lymph node (LN) involvement and progression-free survival (PFS) were recorded. Results: A total of 447 eligible subjects were included in this research. As we analyzed, for HER2, positive and negative, the incidence rates of elevated platelet count were 25.8% and 14.7% (P<0.05). In the Cox proportional hazards model both variables were independent risk factors for BC (for HER2, OR, 0.592, 95% confidence interval, CI, 0.355 to 0.985, P=0.044;f or PLT, OR, 0.998, 95% CI, 0.996 to 1.000, P=0.042). For ER, PR, Ki67 and LN involvement, the differences were not statistically significant (P>0.05). Conclusions: In this research, pre-treatment elevated level of platelet count demostrated a significantrelationship with HER2 amplification/overexpression, and both variables significantly influenced the prognosis of BC. However, elevated platelet count did not exhibit any association with ER, PR, Ki67 and LN involvement.

#Breast cancer #platelet count #HER2 #correlation #prognosis

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!